|
 Sanofi's Praluent, which was developed with Regeneron, and Amgen's
Repatha are both so-called PCSK9 medicines that work in a different
way to existing cholesterol fighters such as statins.
The National Institute for Health and Care Excellence (NICE) said in
draft guidance on Friday that both drugs could be considered for use
by people whose cholesterol is still not under control despite
trying other treatments.
It stressed that the medicines would only be cost-effective with the
promised discounts.
Both drugs cost more than 4,000 pounds ($5,780) per patient a year
in Britain. That is already a lot less than their U.S. list price of
around $14,000, but Sanofi and Amgen have committed to discount the
British price by a further undisclosed amount for the UK National
Health Service.
While Praluent and Repatha are both viewed by analysts as eventual
multi-billion-dollar-a-year sellers, demand for the medicines in
markets worldwide so far has proved disappointing.
(Reporting by Ben Hirschler; editing by Adrian Croft)
[© 2016 Thomson Reuters. All rights
reserved.] Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
